93 related articles for article (PubMed ID: 20675133)
1. SAR studies of non-zinc-chelating MMP-13 inhibitors: improving selectivity and metabolic stability.
Gao DA; Xiong Z; Heim-Riether A; Amodeo L; August EM; Cao X; Ciccarelli L; Collins BK; Harrington K; Haverty K; Hill-Drzewi M; Li X; Liang S; Margarit SM; Moss N; Nagaraja N; Proudfoot J; Roman R; Schlyer S; Keenan LS; Taylor S; Wellenzohn B; Wiedenmayer D; Li J; Farrow NA
Bioorg Med Chem Lett; 2010 Sep; 20(17):5039-43. PubMed ID: 20675133
[TBL] [Abstract][Full Text] [Related]
2. Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors.
Heim-Riether A; Taylor SJ; Liang S; Gao DA; Xiong Z; Michael August E; Collins BK; Farmer BT; Haverty K; Hill-Drzewi M; Junker HD; Mariana Margarit S; Moss N; Neumann T; Proudfoot JR; Keenan LS; Sekul R; Zhang Q; Li J; Farrow NA
Bioorg Med Chem Lett; 2009 Sep; 19(18):5321-4. PubMed ID: 19692239
[TBL] [Abstract][Full Text] [Related]
3. Identification of potent and selective MMP-13 inhibitors.
Wu J; Rush TS; Hotchandani R; Du X; Geck M; Collins E; Xu ZB; Skotnicki J; Levin JI; Lovering FE
Bioorg Med Chem Lett; 2005 Sep; 15(18):4105-9. PubMed ID: 16005220
[TBL] [Abstract][Full Text] [Related]
4. Selective non zinc binding inhibitors of MMP13.
De Savi C; Morley AD; Ting A; Nash I; Karabelas K; Wood CM; James M; Norris SJ; Karoutchi G; Rankine N; Hamlin G; Macfaul PA; Ryan D; Baker SV; Hargreaves D; Gerhardt S
Bioorg Med Chem Lett; 2011 Jul; 21(14):4215-9. PubMed ID: 21669521
[TBL] [Abstract][Full Text] [Related]
5. Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.
Tommasi RA; Weiler S; McQuire LW; Rogel O; Chambers M; Clark K; Doughty J; Fang J; Ganu V; Grob J; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Melton R; Springer C; Walker M; Zhang J; Zhu L; Shultz M
Bioorg Med Chem Lett; 2011 Nov; 21(21):6440-5. PubMed ID: 21937229
[TBL] [Abstract][Full Text] [Related]
6. Extra binding region induced by non-zinc chelating inhibitors into the S1' subsite of matrix metalloproteinase 8 (MMP-8).
Pochetti G; Montanari R; Gege C; Chevrier C; Taveras AG; Mazza F
J Med Chem; 2009 Feb; 52(4):1040-9. PubMed ID: 19173605
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for the highly selective inhibition of MMP-13.
Engel CK; Pirard B; Schimanski S; Kirsch R; Habermann J; Klingler O; Schlotte V; Weithmann KU; Wendt KU
Chem Biol; 2005 Feb; 12(2):181-9. PubMed ID: 15734645
[TBL] [Abstract][Full Text] [Related]
8. 3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding.
Li W; Hu Y; Li J; Thomason JR; DeVincentis D; Du X; Wu J; Hotchandani R; Rush TS; Skotnicki JS; Tam S; Chockalingam PS; Morris EA; Levin JI
Bioorg Med Chem Lett; 2009 Aug; 19(16):4546-50. PubMed ID: 19625186
[TBL] [Abstract][Full Text] [Related]
9. Pyrimidine-2,4,6-Triones: a new effective and selective class of matrix metalloproteinase inhibitors.
Grams F; Brandstetter H; D'Alò S; Geppert D; Krell HW; Leinert H; Livi V; Menta E; Oliva A; Zimmermann G; Gram F; Brandstetter H; D'Alò S; Geppert D; Krell HW; Leinert H; Livi VMenta E; Oliva A; Zimmermann G
Biol Chem; 2001 Aug; 382(8):1277-85. PubMed ID: 11592410
[TBL] [Abstract][Full Text] [Related]
10. Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13.
Freeman-Cook KD; Reiter LA; Noe MC; Antipas AS; Danley DE; Datta K; Downs JT; Eisenbeis S; Eskra JD; Garmene DJ; Greer EM; Griffiths RJ; Guzman R; Hardink JR; Janat F; Jones CS; Martinelli GJ; Mitchell PG; Laird ER; Liras JL; Lopresti-Morrow LL; Pandit J; Reilly UD; Robertson D; Vaughn-Bowser ML; Wolf-Gouviea LA; Yocum SA
Bioorg Med Chem Lett; 2007 Dec; 17(23):6529-34. PubMed ID: 17935984
[TBL] [Abstract][Full Text] [Related]
11. Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12.
Morales R; Perrier S; Florent JM; Beltra J; Dufour S; De Mendez I; Manceau P; Tertre A; Moreau F; Compere D; Dublanchet AC; O'Gara M
J Mol Biol; 2004 Aug; 341(4):1063-76. PubMed ID: 15289103
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization.
La Pietra V; Marinelli L; Cosconati S; Di Leva FS; Nuti E; Santamaria S; Pugliesi I; Morelli M; Casalini F; Rossello A; La Motta C; Taliani S; Visse R; Nagase H; da Settimo F; Novellino E
Eur J Med Chem; 2012 Jan; 47(1):143-52. PubMed ID: 22088955
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13.
Noe MC; Natarajan V; Snow SL; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Carty TJ; Barberia JA; Sweeney FJ; Liras JL; Vaughn M; Hardink JR; Hawkins JM; Tokar C
Bioorg Med Chem Lett; 2005 Jun; 15(11):2808-11. PubMed ID: 15911259
[TBL] [Abstract][Full Text] [Related]
14. Novel matrix metalloproteinase inhibitors: generation of lead compounds by the in silico fragment-based approach.
Takahashi K; Ikura M; Habashita H; Nishizaki M; Sugiura T; Yamamoto S; Nakatani S; Ogawa K; Ohno H; Nakai H; Toda M
Bioorg Med Chem; 2005 Jul; 13(14):4527-43. PubMed ID: 15908222
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.
Dublanchet AC; Ducrot P; Andrianjara C; O'Gara M; Morales R; Compère D; Denis A; Blais S; Cluzeau P; Courté K; Hamon J; Moreau F; Prunet ML; Tertre A
Bioorg Med Chem Lett; 2005 Aug; 15(16):3787-90. PubMed ID: 16002291
[TBL] [Abstract][Full Text] [Related]
16. Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
Schnute ME; O'Brien PM; Nahra J; Morris M; Howard Roark W; Hanau CE; Ruminski PG; Scholten JA; Fletcher TR; Hamper BC; Carroll JN; Patt WC; Shieh HS; Collins B; Pavlovsky AG; Palmquist KE; Aston KW; Hitchcock J; Rogers MD; McDonald J; Johnson AR; Munie GE; Wittwer AJ; Man CF; Settle SL; Nemirovskiy O; Vickery LE; Agawal A; Dyer RD; Sunyer T
Bioorg Med Chem Lett; 2010 Jan; 20(2):576-80. PubMed ID: 20005097
[TBL] [Abstract][Full Text] [Related]
17. Potent, selective pyrimidinetrione-based inhibitors of MMP-13.
Reiter LA; Freeman-Cook KD; Jones CS; Martinelli GJ; Antipas AS; Berliner MA; Datta K; Downs JT; Eskra JD; Forman MD; Greer EM; Guzman R; Hardink JR; Janat F; Keene NF; Laird ER; Liras JL; Lopresti-Morrow LL; Mitchell PG; Pandit J; Robertson D; Sperger D; Vaughn-Bowser ML; Waller DM; Yocum SA
Bioorg Med Chem Lett; 2006 Nov; 16(22):5822-6. PubMed ID: 16942871
[TBL] [Abstract][Full Text] [Related]
18. A new role for old ligands: discerning chelators for zinc metalloproteinases.
Jacobsen FE; Lewis JA; Cohen SM
J Am Chem Soc; 2006 Mar; 128(10):3156-7. PubMed ID: 16522091
[TBL] [Abstract][Full Text] [Related]
19. Potent, selective pyrone-based inhibitors of stromelysin-1.
Puerta DT; Mongan J; Tran BL; McCammon JA; Cohen SM
J Am Chem Soc; 2005 Oct; 127(41):14148-9. PubMed ID: 16218585
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.
Noe MC; Natarajan V; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Otterness I; Bliven MA; Carty TJ; Barberia JT; Sweeney FJ; Liras JL; Vaughn M
Bioorg Med Chem Lett; 2005 Jul; 15(14):3385-8. PubMed ID: 15953722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
